Smith Chas P & Associates PA Cpas Sells 14,965 Shares of Allergan PLC. (AGN)

Smith Chas P & Associates PA Cpas decreased its stake in shares of Allergan PLC. (NYSE:AGN) by 94.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 940 shares of the company’s stock after selling 14,965 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Allergan PLC. were worth $229,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Jacobi Capital Management LLC boosted its holdings in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the last quarter. JNBA Financial Advisors boosted its holdings in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after acquiring an additional 12 shares during the last quarter. Webster Bank N. A. boosted its holdings in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after acquiring an additional 123 shares during the last quarter. Pacific Center for Financial Services boosted its holdings in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after acquiring an additional 475 shares during the last quarter. Finally, Ropes Wealth Advisors LLC boosted its holdings in Allergan PLC. by 31.0% in the first quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock valued at $137,000 after acquiring an additional 136 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

A number of research analysts have commented on the company. Wells Fargo & Company restated an “outperform” rating on shares of Allergan PLC. in a research note on Monday. Royal Bank Of Canada reaffirmed a “buy” rating and set a $285.00 target price on shares of Allergan PLC. in a research report on Wednesday, September 6th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 29th. Cowen and Company reissued an “outperform” rating and issued a $400.00 price objective on shares of Allergan PLC. in a report on Tuesday, August 29th. Finally, BidaskClub downgraded Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $275.49.

Shares of Allergan PLC. (NYSE:AGN) opened at 232.38 on Tuesday. The stock’s 50 day moving average is $235.17 and its 200-day moving average is $237.15. The company has a market cap of $77.69 billion, a PE ratio of 7.08 and a beta of 1.18. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

TRADEMARK VIOLATION WARNING: This news story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://sportsperspectives.com/2017/09/12/smith-chas-p-associates-pa-cpas-sells-14965-shares-of-allergan-plc-agn.html.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply